- Home
- AKAM vs EXAS Comparison
AKAM vs EXAS Comparison
Compare AKAM & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAM
- EXAS
- Stock Information
- Founded
- AKAM 1998
- EXAS 1995
- Country
- AKAM United States
- EXAS United States
- Employees
- AKAM N/A
- EXAS N/A
- Industry
- AKAM Business Services
- EXAS Medical Specialities
- Sector
- AKAM Consumer Discretionary
- EXAS Health Care
- Exchange
- AKAM Nasdaq
- EXAS Nasdaq
- Market Cap
- AKAM 11.4B
- EXAS 10.2B
- IPO Year
- AKAM 1999
- EXAS N/A
- Fundamental
- Price
- AKAM $75.84
- EXAS $52.38
- Analyst Decision
- AKAM Hold
- EXAS Strong Buy
- Analyst Count
- AKAM 16
- EXAS 22
- Target Price
- AKAM $92.60
- EXAS $67.38
- AVG Volume (30 Days)
- AKAM 1.6M
- EXAS 2.8M
- Earning Date
- AKAM 11-06-2025
- EXAS 11-04-2025
- Dividend Yield
- AKAM N/A
- EXAS N/A
- EPS Growth
- AKAM N/A
- EXAS N/A
- EPS
- AKAM 2.82
- EXAS N/A
- Revenue
- AKAM $4,083,251,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- AKAM $6.69
- EXAS $16.68
- Revenue Next Year
- AKAM $5.12
- EXAS $12.08
- P/E Ratio
- AKAM $26.73
- EXAS N/A
- Revenue Growth
- AKAM 3.98
- EXAS 12.55
- 52 Week Low
- AKAM $67.51
- EXAS $38.81
- 52 Week High
- AKAM $106.80
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- AKAM 45.43
- EXAS 56.95
- Support Level
- AKAM $75.59
- EXAS $46.30
- Resistance Level
- AKAM $79.41
- EXAS $56.52
- Average True Range (ATR)
- AKAM 1.80
- EXAS 1.67
- MACD
- AKAM -0.21
- EXAS 0.26
- Stochastic Oscillator
- AKAM 20.93
- EXAS 59.49
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.